Noctrix Health vs Noom
Side-by-side comparison of AI visibility scores, market position, and capabilities
Maker of Nidra, the first FDA-authorized drug-free device for drug-refractory Restless Legs Syndrome. ~$24M ARR; acquired by ResMed for $340M (expected close June 2026).
About
Noctrix Health is a medical device company commercializing Nidra Therapy — the first and only FDA-authorized, drug-free treatment for drug-refractory Restless Legs Syndrome (RLS). The Nidra device uses Tonic Motor Activation (TOMAC) technology to deliver gentle electrical stimulation to the legs, reducing RLS symptoms without pharmaceutical side effects. The FDA granted De Novo authorization in 2023. In August 2025, Noctrix raised $33.5M in combined debt and equity to accelerate U.S. commercialization, reaching an annual revenue run rate of approximately $24M. ResMed signed an agreement in 2026 to acquire Noctrix Health for $340M, with the transaction expected to close around June 1, 2026 — Noctrix''s revenue will be reported within ResMed''s Americas Devices category post-close.
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
About
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Noctrix Health vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.